Further studies will address how this paracrine action may affect tumor-driven angiogenesis upon pharmacological treatments.
and therapeutic insults. By remodeling and exploiting their cellular tumor microenvironment, tumor cells might circumvent these potentially hostile conditions. In keeping with this idea, neoangiogenesis and aberrant activation of endothelial cells largely contribute to fuel the tumor cells and to assist their unlimited growth. 
| MATERIALS AND METHODS

| Cell lines, preparation of conditioned media and drugs
Human oral cavity squamous cell carcinoma-derived cell line HN26, 8 human pharyngeal squamous cell carcinoma-derived cell line HN30, 8 
| MTT assays
Cell viability was evaluated using MTT assay ( Technologies). Images were captured with confocal microscope (Nikon A1 Rsi, MicroPicell Facility). Circularity was calculated based on the following formula F circ = 4πA/P 2 , where A is the area and P the perimeter.
| Data and statistical analysis
Data are representative of three independent experiments unless otherwise stated. Statistical analysis was performed with GraphPad Prism6 using one-way ANOVA and Dunnett's multiple comparisons test. In all experiments P-value of <0.05 was considered significant.
| RESULTS
The squamous cell carcinoma cell lines from the oral cavity (HN26) and from the pharynx (HN30) constitute two well-established in vitro models for HNSCC. Supporting previous works, 3 Western-blot analyses confirmed that the mTOR pathway was constitutively activated in HN26 and HN30 cells, as illustrated by AKT and S6 phosphorylation ( Figure 1A ). The targeting of the PI3K-mTOR signaling pathway with LY294002 (PI3K inhibitor), Rapamycin and Everolimus (mTORC1 inhibitor), and Torin1 (mTOR inhibitor) abolished
FIGURE 1 mTOR Inhibition Reduces Proliferation of Head and Neck Squamous Cell Carcinoma Cells in vitro.
A-B, HN26 and HN30 cell lines were treated overnight with DMSO (CtI), LY294002 (LY, 20 µM), Rapamycin (RP, 50 nM), Everolimus (Evero, 50 nM), and Torin1 (Torin, 100 nM). Western-blots were performed against the indicated targets. GAPDH served as a loading control. C, Cell viability was analyzed by MTT in similarly treated cells for 24 h. Data were normalized to Ctl conditions and are presented as the average + s.e.m. D, Cells were plated for xCELLigence and treated 6 h later with DMSO (CtI), Everolimus (Evero, 50 nM), and Torin1 (Torin, 100 nM), and monitored for 96 h total. Cell index is reported for one representative experiment, done in duplicate. E, HN26 and HN30 cell lines were plated and treated with DMSO (CtI), Everolimus (Evero, 50 nM) and Torin1 (Torin, 100 nM) and analyzed for crystal violet staining, at day 4. Data are presented the average + s.e.m. Panels are representative of two or more independent experiments. *P < 0.05, **P < 0, 01, ***P < 0.001, ****P < 0.0001, using one-way ANOVA and Dunnett's multiple comparisons test S6 activation in both cell lines, while AKT phosphorylation on S473 was strongly reduced only with Torin1 ( Figure 1A ). To next evaluate the impact of such treatments on cell viability, we examined the levels of full-length nuclear poly (ADP-ribose) polymerase PARP, which is cleaved during apoptosis. 9 Western-blot analyses showed that PARP levels were markedly reduced upon mTOR inhibition, consistent with increased cell death ( Figure 1B ). Of note, Rapamycin was less efficient than Everolimus and Torin1 in inducing PARP processing in HN26 cells ( Figure 1B) . These results prompted us to consider Everolimus and Torin1 as interesting drugs to target the mTOR pathway in both HN26 
somehow less potent in these experimental settings ( Figure 1C ).
Interestingly, xCELLigence impedance measurement of proliferation clearly showed that both drugs decrease their growth capability ( Figure 1D ). The impact of Everolimus and Torin1 on cell proliferation was reinforced by their ability to blunt clonogenicity ( Figure 1E ).
Collectively, these results confirm that the PI3K-mTOR signaling pathway is required to sustain survival and proliferation of HNSCC cell Figure 4B ). In these conditions, the conditioned media from Torin1-incubated HN30 (CM30-Torin) was less potent in inducing the phosphorylation of FAK ( Figure 4C ). Overall, this suggests that mTOR inhibition led to VEGF over-production released in the external medium, which may in turn alter the endothelial behavior.
| DISCUSSION
In this study, we confirmed the potent action of mTOR inhibition on HNSCC proliferation. We also unveiled an unexpected bystander impact on endothelial cells. Indeed, our data demonstrated that the 3 FIGURE 3 Bystander Effect of mTOR Inhibition in HN26 on Endothelial Cell Mobility. A, HUVEC were grown in condition medium (CM) from HN26 cells (CM26) that priory received DMSO (Ctl), Everolimus (Evero), and Torin1 (Torin). Impedance was monitored for 8 h using xCELLigence. B, HUVEC were cultured in DMEM (CtI), or in CM26-Ctl, CM26-Evero, and CM26-Torin for 2 h. Levels of phosphorylated FAK (pFAK) were assessed by Western-blot. GAPDH served as a loading control. Normalized intensities are reported below the scans. C, HUVEC were cultured on uncoated glass coverslips in DMEM (Ctl) supplemented with DMSO, Everolimus (Evero, 50 nM), and Torin1 (Torin, 100 nM). Alternatively, cells were plated in CM26-Ctl, CM26-Evero, and CM26-Torin. Cells were fixed 2 h later and labeled for actin with phalloidin (green). Nuclei were counterstained with DAPI (blue). D, Cell circulatory index was calculated based on actin staining on n ≥ 30. E, Similarly to panel C, endothelial cells were plated in CM26-Ctl, CM26-Evero, and CM26-Torin. Cells were fixed 2 h later and labeled for paxillin (green). These findings are somehow reminiscent of our recent data in brain tumors highlighting the propagation of adhesion and migration cues via extracellular vesicles. 20 In line with this, VEGF is transported within breast cancer cell-released extracellular vesicles released. 21 An interesting angle of research will be to explore in-depth the possible participation of mTOR in angiogenesis, in coordination with already known factors. For instance, here we show that VEGF might mediate this paracrine action. In keeping with this idea, the combination of Everolimus with Lenvatinib, a multitargeted tyrosine kinase inhibitor that inhibits VEGFR and FGFR exerted higher antitumor activity than monotherapy in model of human renal cell carcinoma xenotransplantation mice. 22 To conclude, while mTOR inhibition strongly restrains tumor growth, undesired accompanying effects might potentiate endothelial cell activity in vitro. Future works will decipher the exact molecular mechanisms involved and whether this phenomenon contributes in fine to tumor-driven angiogenesis.
